Besides its approval by the FDA, the relevance for testing TRH and its analogs for ameliorating breathing disorder’s symptoms in OSA is the high expression of TRH receptors in the hypoglossal motor nucleus, the high content of afferent connections that this nucleus receives from TRH-synthesizing neurons, and the excitatory actions of the peptides in that nucleus. This evidence concerns the gene TRH and obstructive sleep apnea syndrome.